REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.69
+0.07 (0.81%)
At close: Apr 28, 2026, 4:00 PM EDT
8.70
+0.01 (0.12%)
After-hours: Apr 28, 2026, 7:56 PM EDT
REGENXBIO Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 28.75, with a low estimate of 12 and a high estimate of 50. The average target predicts an increase of 230.84% from the current stock price of 8.69.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 9, 2026.
Analyst Ratings
The average analyst rating for REGENXBIO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +245.22% | Mar 9, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +95.63% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $32 | Strong Buy | Maintains | $34 → $32 | +268.24% | Feb 10, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +38.09% | Feb 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $25 → $18 | Buy | Maintains | $25 → $18 | +107.13% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
257.72M
from 170.44M
Increased by 51.21%
Revenue Next Year
306.90M
from 257.72M
Increased by 19.08%
EPS This Year
-2.52
from -3.76
EPS Next Year
-2.87
from -2.52
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 408.5M | 563.3M | ||||||
| Avg | 257.7M | 306.9M | ||||||
| Low | 132.3M | 155.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 139.6% | 118.6% | ||||||
| Avg | 51.2% | 19.1% | ||||||
| Low | -22.4% | -39.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.69 | 0.64 | ||||||
| Avg | -2.52 | -2.87 | ||||||
| Low | -4.77 | -6.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.